The oncology-focused drug developer sourced $77m in the series D round, which was co-led by China Life Healthcare Fund.

China-based biomedical research technology provider Biocytogen closed a RMB543m ($77m) series D round on Thursday that was co-led by a private equity fund owned by insurance firm China Life. China Life Healthcare Fund co-led the round with SDIC Venture Capital, a fund management subsidiary of state-owned investment holding group State Development and Investment Corp (SDIC).…

The rest of this content is only accessible to Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.